Metabolic & Endocrine
Polycystic Ovarian Syndrome (PCOS)
1
Pipeline Programs↗
3
Active Trials↗
4
Companies Involved↗
Polycystic Ovarian Syndrome (PCOS) is an early-stage landscape with 1 program across 4 companies. The most active players are AstraZeneca, Merck & Co., Ferring.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
11
clinical trials
Completed7 · 64%
Recruiting3 · 27%
Unknown status1 · 9%
Clinical Trials
Trial Activity
11 trials
Vitamin D and Polycystic Ovarian Syndrome (PCOS)
Recruiting·—·Phase 2·NCT03989778·300 enrolled
Effect of Diaphragmatic Breathing on Sleep Disorders in Polycystic Ovarian Syndrome
Recruiting·—·Preclinical·NCT07698925·54 enrolled
Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility
Completed·—·N/A·NCT07058675·156 enrolled
Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS)
Unknown status·—·Phase 3·NCT02305693·140 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)